Molecular therapy for Myocardial Infarction: Verapamil, a calcium channel blocker and an antihypertensive drug, inhibits DNA damage responses, increases telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up-regulation of PNUTS, 25/December/2016, 11.19 pm

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others. What we say:  On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction: Verapamil, a calcium channel blocker and […]

Natural product-derived PD-L1 pathway blockade enhances the efficacy of Cancer immunotherapy: Honokiol, isolated from Magnolia-grandiflora/dealbata/obovata/officinalis, inhibits the expression of PD-L1, inhibits inflammatory signalling and the number of tumor-infiltrating lymphocytes and macrophages, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival via up-regulation of its target gene, 25/December/2016, 10.37 pm

Introduction:What they say: A recent study from Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, 1515 Holcombe Boulevard, Houston, TX 77030, USA shows that “Deubiquitination and Stabilization of PD-L1 by CSN5.” This study was published in the 12 December 2016 issue of Cancer cell (one of the best journals in […]

Natural product-derived therapy for enhancing anti-cancer immunity: Emodin (6-methyl-1,3,8-trihydroxy anthraquinone), found in Polygonum multiflorum, decreases the level of LATS1/2 (large tumor suppressor 1 and 2), increases immunogenicity of tumors, enhances anti-tumor immune responses, and inhibits tumor growth via down regulation of its target gene, 25/December/2016, 10.00 pm

Introduction: What they say:  A study from the Department of Pharmacology and Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093, USA shows that “The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity.” This study was published in the 1 December 2016 issue of the journal “Cell” [the number 1 journal in General Biology with […]

Therapeutic insights into “awakening the sleeping/cancer-protecting angels” in mutant p53-expressing human tumors: PAPD5 (Poly(A) RNA Polymerase D5, Non-Canonical) increases the expression of tumor suppressor p53 homologue TA-p73/p63, PTEN, TPM1, TIMP3, BTG2, PDCD4, SPRY1/2 and CCM1/KRIT1 and induces regression of p53-mutated human tumors via down regulation of its target gene, 25/December/2016, 9.18 pm

From Significance of the study to Public health relevance: Given that: (1) Cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant […]

Natural product-derived therapy for Human Leukemias: Boehmenan, found in stem of Caulis clematidis armandii and Hibiscus ficulneus, suppresses B-Cell and myeloid leukemias via up regulation of the tumor suppressor IRF4, 25/December/2016, 12.03 am

Introduction: What they say Noble laureate in Physiology/Medicine (1975) Prof. David Baltimore, from California Institute of Technology, California, USA, had reported in the July 8, 2014 issue of the Journal “Blood” that: “Dual mechanisms by which MiR-125b represses IRF4 to induce myeloid/B-cell leukemias.”  What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-derived therapy for Human Leukemias: Boehmenan, […]

Molecular therapy for Myocardial Infarction: KGF inhibits DNA damage responses, increases telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up-regulation of PNUTS, 24/December/2016, 11.35 pm

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published in the 7 March  2013 issue of Nature  by Prof Dimmler, Boon, and others. What we say:  On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Molecular therapy for Myocardial Infarction: KGF inhibits DNA damage responses, increases […]